JP2023524518A5 - - Google Patents
Info
- Publication number
- JP2023524518A5 JP2023524518A5 JP2022566660A JP2022566660A JP2023524518A5 JP 2023524518 A5 JP2023524518 A5 JP 2023524518A5 JP 2022566660 A JP2022566660 A JP 2022566660A JP 2022566660 A JP2022566660 A JP 2022566660A JP 2023524518 A5 JP2023524518 A5 JP 2023524518A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- pharmaceutical
- powder
- crystalline
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2006390.5A GB202006390D0 (en) | 2020-04-30 | 2020-04-30 | Novel treatments |
| GB2006390.5 | 2020-04-30 | ||
| PCT/EP2021/061464 WO2021219881A1 (en) | 2020-04-30 | 2021-04-30 | 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-quinoline-3-carboxamide potassium salt for treating inflammatory bowel diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023524518A JP2023524518A (ja) | 2023-06-12 |
| JP2023524518A5 true JP2023524518A5 (enExample) | 2024-05-10 |
| JP7702427B2 JP7702427B2 (ja) | 2025-07-03 |
Family
ID=71080611
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022566661A Pending JP2023524519A (ja) | 2020-04-30 | 2021-04-30 | 炎症性腸疾患の治療 |
| JP2022566660A Active JP7702427B2 (ja) | 2020-04-30 | 2021-04-30 | 炎症性腸疾患を治療するための５－クロロ－４－ヒドロキシ－１－メチル－２－オキソ－ｎ－フェニル－キノリン－３－カルボキサミドカリウム塩 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022566661A Pending JP2023524519A (ja) | 2020-04-30 | 2021-04-30 | 炎症性腸疾患の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20230167064A1 (enExample) |
| EP (2) | EP4142725A1 (enExample) |
| JP (2) | JP2023524519A (enExample) |
| KR (2) | KR20230018386A (enExample) |
| CN (2) | CN115916200A (enExample) |
| AU (2) | AU2021266154A1 (enExample) |
| CA (2) | CA3177000A1 (enExample) |
| GB (2) | GB202006390D0 (enExample) |
| WO (2) | WO2021219879A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202006390D0 (en) * | 2020-04-30 | 2020-06-17 | Aqilion Ab | Novel treatments |
| JP2023527782A (ja) * | 2020-05-21 | 2023-06-30 | ステムシナジー セラピューティクス， インク． | Ｎｏｔｃｈ阻害剤及びその使用 |
| CN115120727B (zh) * | 2022-06-16 | 2024-02-23 | 甘肃农业大学 | S100a9抑制剂在制备防治c型产气荚膜梭菌感染性腹泻药物中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52670B1 (en) | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
| SE9400809D0 (sv) * | 1994-03-10 | 1994-03-10 | Pharmacia Ab | New use of quinoline-3-carboxamide compounds |
| EP2061440A2 (en) * | 2007-04-04 | 2009-05-27 | Sigmoid Pharma Limited | A pharmaceutical composition of tacrolimus |
| BR112012002124A2 (pt) * | 2009-07-30 | 2015-09-15 | Teva Pharma | tratamento da doença de crohn com laquinimode. |
| AU2011274496B2 (en) * | 2010-07-09 | 2016-03-10 | Teva Pharmaceutical Industries Ltd. | Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof |
| JP5934202B2 (ja) * | 2010-07-09 | 2016-06-15 | テバ ファーマシューティカル インダストリーズ リミティド | ５−クロロ−４−ヒドロキシ−１−メチル−２−オキソ−ｎ−フェニル−１，２−ジヒドロキノリン−３−カルボキサミドと、その塩及びその使用 |
| KR20130065728A (ko) * | 2010-10-14 | 2013-06-19 | 임뮤나르 에이비 | Ahr 활성화제로서의 1,2-디히드로-4-히드록시-2-옥소-퀴놀린-3-카르복사닐리드 |
| US9200046B2 (en) * | 2011-06-29 | 2015-12-01 | Cornell University | Reporter system for high throughput screening of compounds and uses thereof |
| GB202006390D0 (en) * | 2020-04-30 | 2020-06-17 | Aqilion Ab | Novel treatments |
-
2020
- 2020-04-30 GB GBGB2006390.5A patent/GB202006390D0/en not_active Ceased
-
2021
- 2021-04-30 AU AU2021266154A patent/AU2021266154A1/en active Pending
- 2021-04-30 KR KR1020227041920A patent/KR20230018386A/ko not_active Ceased
- 2021-04-30 JP JP2022566661A patent/JP2023524519A/ja active Pending
- 2021-04-30 CA CA3177000A patent/CA3177000A1/en active Pending
- 2021-04-30 EP EP21723216.4A patent/EP4142725A1/en not_active Withdrawn
- 2021-04-30 EP EP21723215.6A patent/EP4142724A1/en active Pending
- 2021-04-30 WO PCT/EP2021/061462 patent/WO2021219879A1/en not_active Ceased
- 2021-04-30 US US17/922,043 patent/US20230167064A1/en not_active Abandoned
- 2021-04-30 US US17/922,072 patent/US20230202982A1/en not_active Abandoned
- 2021-04-30 KR KR1020227041908A patent/KR20230024892A/ko not_active Ceased
- 2021-04-30 JP JP2022566660A patent/JP7702427B2/ja active Active
- 2021-04-30 CA CA3176994A patent/CA3176994A1/en active Pending
- 2021-04-30 AU AU2021262514A patent/AU2021262514A1/en active Pending
- 2021-04-30 CN CN202180043624.XA patent/CN115916200A/zh active Pending
- 2021-04-30 WO PCT/EP2021/061464 patent/WO2021219881A1/en not_active Ceased
- 2021-04-30 GB GB2207709.3A patent/GB2605894B/en active Active
- 2021-04-30 CN CN202180044567.7A patent/CN115768429B/zh active Active